The concurrent expression with resulting cross‐talk of hormones (estrogen and/or progesterone) and HER2 may distinctly affect cancer outcomes and the natural history of disease in patients with HER2+ breast cancer.1, 3. This evidence concerns the gene ERBB2 and breast carcinoma.